sulfamethoxazole has been researched along with Colitis Gravis in 11 studies
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)
sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We recently treated a patient with intractable ulcerative colitis complicated with Pneumocystis carinii pneumonia in whom sulfamethoxazole/trimethoprim caused pneumonitis." | 7.70 | Drug-induced pneumonitis caused by sulfamethoxazole, trimethoprim during treatment of Pneumocystis carinii pneumonia in a patient with refractory ulcerative colitis. ( Hirata, K; Kudoh, S; Kuroki, T; Matsumoto, T; Moriyama, Y; Oshitani, N, 1998) |
| "We recently treated a patient with intractable ulcerative colitis complicated with Pneumocystis carinii pneumonia in whom sulfamethoxazole/trimethoprim caused pneumonitis." | 3.70 | Drug-induced pneumonitis caused by sulfamethoxazole, trimethoprim during treatment of Pneumocystis carinii pneumonia in a patient with refractory ulcerative colitis. ( Hirata, K; Kudoh, S; Kuroki, T; Matsumoto, T; Moriyama, Y; Oshitani, N, 1998) |
| "To evaluate the potential for pharmacokinetic interactions between MMX mesalamine and amoxicillin, ciprofloxacin extended release (XR), metronidazole, or sulfamethoxazole in four open-label, randomized, placebo-controlled, two-period crossover studies." | 2.79 | Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. ( Barrett, K; Corcoran, M; Inglis, S; Martin, P; Pierce, D; Preston, P; Thompson, TN; Willsie, SK, 2014) |
| "- 203 patients with Crohn's disease (n = 154) or colitis ulcerosa (n = 49) underwent elective surgery from January 1st, 1978 to April 30th, 1985." | 1.27 | [Surgical treatment of Crohn disease and ulcerative colitis in standardized conditions]. ( Pfeiffer, M, 1986) |
| "Salmonella colitis is an acute ulcerative colitis occurring in enteric salmonellosis." | 1.26 | [Salmonella colitis]. ( Blum, AL; Deyhle, P; Giger, M; Jaeger, M; Nüesch, HJ; Seefeld, U; Siebenmann, R; Wüst, W, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karpińska, G | 1 |
| Dobrowolski, JC | 1 |
| Yinda, CK | 1 |
| Rector, A | 1 |
| Zeller, M | 1 |
| Conceição-Neto, N | 1 |
| Heylen, E | 1 |
| Maes, P | 1 |
| Ghogomu, SM | 1 |
| Van Ranst, M | 1 |
| Matthijnssens, J | 1 |
| Arthanari, SK | 1 |
| Vanitha, J | 1 |
| Ganesh, M | 1 |
| Venkateshwaran, K | 1 |
| de Lama Caro-Patón, G | 1 |
| García-Salido, A | 1 |
| Iglesias-Bouzas, MI | 1 |
| Guillén, M | 1 |
| Cañedo-Villaroya, E | 1 |
| Martínez-Romera, I | 1 |
| Serrano-González, A | 1 |
| Casado-Flores, J | 1 |
| Gale, P | 2 |
| Chen, X | 2 |
| Li, H | 1 |
| Lucero-Prisno, DE | 1 |
| Abdullah, AS | 1 |
| Huang, J | 1 |
| Laurence, C | 1 |
| Liang, X | 1 |
| Ma, Z | 1 |
| Mao, Z | 1 |
| Ren, R | 1 |
| Wu, S | 1 |
| Wang, N | 1 |
| Wang, P | 2 |
| Wang, T | 1 |
| Yan, H | 1 |
| Zou, Y | 1 |
| Olsen, KM | 1 |
| Gabler, NK | 1 |
| Rademacher, CJ | 1 |
| Schwartz, KJ | 1 |
| Schweer, WP | 1 |
| Gourley, GG | 1 |
| Patience, JF | 1 |
| Rauch, JC | 1 |
| Stokes, RS | 1 |
| Shike, DW | 1 |
| Luebbe, KM | 1 |
| Stalker, LA | 1 |
| Klopfenstein, TJ | 1 |
| Funston, RN | 1 |
| Unger, PA | 1 |
| Lighaam, LC | 1 |
| Vermeulen, E | 1 |
| Kruithof, S | 1 |
| Makuch, M | 1 |
| Culver, EL | 1 |
| van Bruggen, R | 1 |
| Remmerswaal, EBM | 1 |
| Ten Berge, IJM | 1 |
| Emmens, RW | 1 |
| Niessen, HWM | 1 |
| Barnes, E | 1 |
| Wolbink, GJ | 1 |
| van Ham, SM | 1 |
| Rispens, T | 1 |
| Liang, JX | 1 |
| Lin, J | 1 |
| Liu, J | 1 |
| Wang, X | 1 |
| Zhang, T | 1 |
| Li, J | 1 |
| Wu, Y | 2 |
| Venier, M | 1 |
| Salamova, A | 1 |
| Gonçales, VR | 1 |
| Lian, J | 1 |
| Gautam, S | 1 |
| Tilley, RD | 1 |
| Gooding, JJ | 1 |
| Kandel, YR | 1 |
| Bradley, CA | 1 |
| Chilvers, MI | 1 |
| Mathew, FM | 1 |
| Tenuta, AU | 1 |
| Smith, DL | 1 |
| Wise, KA | 1 |
| Mueller, DS | 1 |
| Lu, N | 1 |
| Lu, M | 1 |
| Liu, P | 1 |
| Xu, H | 1 |
| Qiu, X | 1 |
| Hu, S | 1 |
| Bai, S | 1 |
| Wu, J | 1 |
| Xue, S | 1 |
| Dai, X | 1 |
| Dharmage, SC | 1 |
| Abramson, MJ | 1 |
| Erbas, B | 1 |
| Bennett, CM | 1 |
| Svanes, C | 1 |
| Hui, J | 1 |
| Axelrad, C | 1 |
| Lowe, AJ | 1 |
| Lodge, CJ | 1 |
| Hoshi, M | 1 |
| Osawa, Y | 1 |
| Nakamoto, K | 1 |
| Morita, N | 1 |
| Yamamoto, Y | 1 |
| Ando, T | 1 |
| Tashita, C | 1 |
| Nabeshima, T | 1 |
| Saito, K | 1 |
| Gianesello, L | 1 |
| Del Prete, D | 1 |
| Ceol, M | 1 |
| Priante, G | 1 |
| Calò, LA | 1 |
| Anglani, F | 1 |
| Vekaria, HJ | 1 |
| Hubbard, WB | 1 |
| Scholpa, NE | 1 |
| Spry, ML | 1 |
| Gooch, JL | 1 |
| Prince, SJ | 1 |
| Schnellmann, RG | 1 |
| Sullivan, PG | 1 |
| Zhang, Q | 1 |
| Hu, R | 1 |
| Gu, Z | 1 |
| Zhang, M | 1 |
| Zhang, Z | 1 |
| Peng, Y | 1 |
| Feng, L | 1 |
| Li, X | 3 |
| Zhao, C | 1 |
| Sarfaraz, K | 1 |
| Gao, L | 1 |
| Wang, H | 1 |
| Wan, C | 1 |
| Leng, J | 1 |
| Yang, P | 1 |
| Gao, X | 1 |
| Gao, J | 1 |
| Emam, HE | 1 |
| Saad, NM | 1 |
| Abdallah, AEM | 1 |
| Ahmed, HB | 1 |
| Palombo, M | 1 |
| Ianus, A | 1 |
| Guerreri, M | 1 |
| Nunes, D | 1 |
| Alexander, DC | 1 |
| Shemesh, N | 1 |
| Zhang, H | 1 |
| Xiong, Q | 1 |
| Liu, YS | 1 |
| Hu, LX | 1 |
| Shi, ZQ | 1 |
| Ying, GG | 1 |
| Chen, R | 1 |
| Hong, X | 1 |
| Yan, S | 1 |
| Zha, J | 1 |
| Gu, H | 1 |
| Zhong, Q | 1 |
| Zeng, Y | 1 |
| Zhang, S | 1 |
| Bu, Y | 1 |
| Farghali, M | 1 |
| Mayumi, M | 1 |
| Syo, K | 1 |
| Satoshi, A | 1 |
| Seiichi, Y | 1 |
| Takashima, S | 1 |
| Ono, H | 1 |
| Ap, Y | 1 |
| Yamashiro, T | 1 |
| Ahmed, MM | 1 |
| Kotb, S | 1 |
| Iwasaki, M | 1 |
| Ihara, I | 1 |
| Umetsu, K | 1 |
| Hu, B | 1 |
| Wang, Y | 2 |
| Quan, J | 1 |
| Huang, K | 1 |
| Gu, X | 1 |
| Zhu, J | 1 |
| Yan, Y | 1 |
| Wu, P | 1 |
| Yang, L | 1 |
| Zhao, J | 1 |
| Koók, L | 1 |
| Nemestóthy, N | 1 |
| Bélafi-Bakó, K | 1 |
| Bakonyi, P | 1 |
| Luo, X | 1 |
| Zhang, F | 1 |
| Li, Q | 1 |
| Xia, Q | 1 |
| Li, Z | 1 |
| Ye, W | 1 |
| Li, S | 1 |
| Ge, C | 1 |
| Zakkula, A | 1 |
| Pulipati, S | 1 |
| Dittakavi, S | 1 |
| Bestha, RM | 1 |
| Zainuddin, M | 1 |
| Trivedi, RK | 1 |
| Mullangi, R | 1 |
| Lo, GH | 1 |
| Lin, CW | 1 |
| Tai, CM | 1 |
| Perng, DS | 1 |
| Chen, IL | 1 |
| Yeh, JH | 1 |
| Lin, HC | 1 |
| Rocha, GS | 1 |
| Silva, MKL | 1 |
| Cesarino, I | 1 |
| Hazzaa, SM | 1 |
| Abdelaziz, SAM | 1 |
| Abd Eldaim, MA | 1 |
| Abdel-Daim, MM | 1 |
| Elgarawany, GE | 1 |
| Larsson, P | 1 |
| Ljuslinder, I | 1 |
| Öhlund, D | 1 |
| Myte, R | 1 |
| Löfgren-Burström, A | 1 |
| Zingmark, C | 1 |
| Ling, A | 1 |
| Edin, S | 1 |
| Palmqvist, R | 1 |
| Murthi, P | 1 |
| Rajaraman, G | 1 |
| Erwich, JJHM | 1 |
| Dimitriadis, E | 1 |
| Yoon, HG | 1 |
| Oh, D | 1 |
| Ahn, YC | 1 |
| Noh, JM | 1 |
| Pyo, H | 1 |
| Cho, WK | 1 |
| Song, YM | 1 |
| Park, M | 1 |
| Hwang, NY | 1 |
| Sun, JM | 1 |
| Kim, HK | 1 |
| Zo, JI | 1 |
| Shim, YM | 1 |
| Persano, A | 1 |
| Quaranta, F | 1 |
| Taurino, A | 1 |
| Siciliano, PA | 1 |
| Iannacci, J | 1 |
| Malekbala, MR | 1 |
| Soltani, S | 1 |
| Abdul Rashid, S | 1 |
| Abdullah, LC | 1 |
| Rashid, U | 1 |
| Nehdi, IA | 1 |
| Choong, TSY | 1 |
| Teo, SH | 1 |
| Xu, P | 1 |
| Yan, F | 1 |
| Zhao, Y | 1 |
| Sun, S | 1 |
| Ying, L | 1 |
| Quinzi, V | 1 |
| Caruso, S | 1 |
| Mummolo, S | 1 |
| Nota, A | 1 |
| Angelone, AM | 1 |
| Mattei, A | 1 |
| Gatto, R | 1 |
| Marzo, G | 1 |
| Xin, W | 1 |
| Severino, J | 1 |
| Venkert, A | 1 |
| Yu, H | 1 |
| Knorr, D | 1 |
| Yang, JM | 1 |
| Carlson, L | 1 |
| Hicks, R | 1 |
| De Rosa, I | 1 |
| Beckmann, NA | 1 |
| Bitsch, RG | 1 |
| Schonhoff, M | 1 |
| Siebenrock, KA | 1 |
| Schwarze, M | 1 |
| Jaeger, S | 1 |
| Pierce, D | 1 |
| Corcoran, M | 1 |
| Martin, P | 1 |
| Barrett, K | 1 |
| Inglis, S | 1 |
| Preston, P | 1 |
| Thompson, TN | 1 |
| Willsie, SK | 1 |
| Kressner, MS | 1 |
| Williams, SE | 1 |
| Biempica, L | 1 |
| Das, KM | 1 |
| Oshitani, N | 1 |
| Matsumoto, T | 1 |
| Moriyama, Y | 1 |
| Kudoh, S | 1 |
| Hirata, K | 1 |
| Kuroki, T | 1 |
| Onderdonk, AB | 1 |
| Hermos, JA | 1 |
| Dzink, JL | 1 |
| Bartlett, JG | 1 |
| Giger, M | 1 |
| Nüesch, HJ | 1 |
| Seefeld, U | 1 |
| Jaeger, M | 1 |
| Wüst, W | 1 |
| Siebenmann, R | 1 |
| Deyhle, P | 1 |
| Blum, AL | 1 |
| Tkaczewski, W | 1 |
| Niedzielska, H | 1 |
| Pfeiffer, M | 1 |
| Van der Waaij, D | 1 |
| Cohen, BJ | 1 |
| Anver, MR | 1 |
| Flavell Matts, SG | 1 |
| Savidge, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Amoxicillin Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01442688] | Phase 1 | 62 participants (Actual) | Interventional | 2011-10-07 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Sulfamethoxazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01469637] | Phase 1 | 44 participants (Actual) | Interventional | 2011-11-07 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Ciprofloxacin XR Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01402947] | Phase 1 | 30 participants (Actual) | Interventional | 2011-07-25 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Metronidazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01418365] | Phase 1 | 30 participants (Actual) | Interventional | 2011-08-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01442688)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | h*ug/ml (Mean) |
|---|---|
| Amoxicillin + MMX Placebo | 27.8 |
| Amoxicillin + MMX Mesalazine/Mesalamine | 28.3 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01442688)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ug/ml (Mean) |
|---|---|
| Amoxicillin + MMX Placebo | 10.3 |
| Amoxicillin + MMX Mesalazine/Mesalamine | 10.2 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure of how much and how long a drug stays in a body. (NCT01469637)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | h*ug/ml (Mean) |
|---|---|
| Sulfamethoxazole + MMX Placebo | 786 |
| Sulfamethoxazole + MMX Mesalazine/Mesalamine | 909 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01469637)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ug/ml (Mean) |
|---|---|
| Sulfamethoxazole + MMX Placebo | 89.1 |
| Sulfamethoxazole + MMX Mesalazine/Mesalamine | 100 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01402947)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng*h/ml (Mean) |
|---|---|
| MMX Placebo + Ciprofloxacin | 7805 |
| MMX Mesalazine/Mesalamine + Ciprofloxacin | 7934 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01402947)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng/ml (Mean) |
|---|---|
| MMX Placebo + Ciprofloxacin | 1455 |
| MMX Mesalazine/Mesalamine + Ciprofloxacin | 1433 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01418365)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng*h/ml (Mean) |
|---|---|
| Metronidazole + MMX Placebo | 217686 |
| Metronidazole + MMX Mesalazine/Mesalamine | 215809 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01418365)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng/ml (Mean) |
|---|---|
| Metronidazole + MMX Placebo | 28193 |
| Metronidazole + MMX Mesalazine/Mesalamine | 28057 |
1 review available for sulfamethoxazole and Colitis Gravis
| Article | Year |
|---|---|
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Am | 2013 |
2 trials available for sulfamethoxazole and Colitis Gravis
9 other studies available for sulfamethoxazole and Colitis Gravis
| Article | Year |
|---|---|
Salmonellosis complicating ulcerative colitis. Treatment with trimethoprim-sulfamethoxazole.
Topics: Adult; Colitis, Ulcerative; Female; Humans; Salmonella Infections; Salmonella paratyphi B; Sulfameth | 1982 |
Drug-induced pneumonitis caused by sulfamethoxazole, trimethoprim during treatment of Pneumocystis carinii pneumonia in a patient with refractory ulcerative colitis.
Topics: Adult; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Colitis, Ulcerative; Diagnosis, Differen | 1998 |
Protective effect of metronidazole in experimental ulcerative colitis.
Topics: Animals; Carrageenan; Cecum; Colitis, Ulcerative; Enterobacter; Escherichia coli; Gentamicins; Guine | 1978 |
[Salmonella colitis].
Topics: Adult; Colitis, Ulcerative; Drug Combinations; Feces; Humans; Male; Middle Aged; Salmonella Infectio | 1979 |
[Biseptol in the treatment of ulcerative colitis].
Topics: Adolescent; Adult; Aged; Colitis, Ulcerative; Drug Evaluation; Female; Humans; Male; Middle Aged; Su | 1975 |
[Surgical treatment of Crohn disease and ulcerative colitis in standardized conditions].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Colitis, Ulcerative; Crohn | 1986 |
Mitigation of experimental inflammatory bowel disease in guinea pigs by selective elimination of the aerobic gram-negative intestinal microflora.
Topics: Animals; Bacteria; Body Weight; Carrageenan; Cecum; Colitis, Ulcerative; Colon; Disease Models, Anim | 1974 |
Ulcerative colitis, diverticulitis and the irritable colon syndrome.
Topics: Colitis, Ulcerative; Colonic Diseases, Functional; Diverticulitis, Colonic; Humans; Parasympatholyti | 1972 |
Trimethoprim and sulphamethoxazole in ulcerative colitis.
Topics: Adult; Aged; Colitis, Ulcerative; Female; Folic Acid Antagonists; Humans; Male; Middle Aged; Pyrimid | 1969 |